FSD Pharma Inc. announces acquisition to expand in Newfoundland for production and sales

•Strategic investment of $40 million to bring economic benefits to province of Newfoundland
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC: FSDDF) is pleased to announce a binding agreement to purchase 51% of Atlantic Island Cannabis Inc. (to be renamed FSD Atlantic Pharma Inc.) effective July 4, 2018. The agreement involves a strategic investment of $40 million to drive production and sales of legal cannabis in the province of Newfoundland. In the first phase of the project, an indoor high quality 45,000 square foot cannabis production facility will be set up in Freshwater, Carbonear, Newfoundland. This site is expected to bring about economic benefits for the province and to create 200 local, management and construction jobs through a phased expansion approach. Phase two of the project will involve a further expansion of the indoor grow facility to up to approximately 300,000 square feet for the production and processing of legal cannabis. read more

FSD Pharma Announces Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma (CSE: HUGE) (OTC: FSDDF) (“FSD Pharma“), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI“) with Canntab Therapeutics Limited (CSE: PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License“), and will provide Canntab with space at its 620,000 square foot facility (the “FSD Facility“), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction“). read more

FSD Pharma Breaks All-Time Monthly Stock Volume Trading Record

FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the one month period of trading between May 29, 2018 and June 28, 2018, the company traded exactly 869,232,894 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). This is the largest total quantity of share volume ever traded by a CSE listed issuer within a one month period of consecutive days of trading. Comparatively, the largest amount traded prior on the CSE in a one month period of consecutive days was 380,976,411. This is a new record as confirmed by the CSE. read more

FSD Pharma Inc. announces $55 million dollar indoor cannabis grow partnership expansion at its Cobourg facility

FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to provide an update on the progress of the joint venture between its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma) and Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”). read more

FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board

FSD Pharma Inc.  (“FSD Pharma” or the “Company”) (CSE:HUGE), announced today the appointment of Dr. Zohar Koren as Head of the Company’s Scientific Advisory Board. This announcement follows the recently announced strategic collaboration of FSD Pharma with SciCann Therapeutics Inc. as its lead scientific platform and center of innovation in Israel, dedicated to the development of disruptive cannabinoid-based therapies backed up by solid science and rigorous clinical studies. read more

FSD Pharma Breaks All-Time Weekly Stock Volume Trading Record

FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the last 5 consecutive days of trading, the company traded exactly 269,961,050 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). This is the largest total quantity of share volume ever traded by a CSE listed issuer within five consecutive days of trading. Comparatively, the largest amount traded prior was also achieved by FSD when it traded 259,230,820 shares in a 5 consecutive trading day period between May 29, 2018 and June 4, 2018. This is a new record as confirmed by the CSE. read more

FSD Pharma Inc. Announces a Partnership Agreement with Cannara Biotech Inc. to Allow for Indoor Grow Space to Increase to a Combined 1,245,000 Square Feet

FSD Pharma Inc. (“FSD Pharma” or “The Company”) (CSE:HUGE), announced the signing of a partnership agreement between FV Pharma Inc. (“FV Pharma”), a wholly-owned subsidiary of the Company, and Cannara Biotech Inc. (“Cannara”) effective May 31, 2018. The agreement creates the ability for the Company to  become the largest indoor medical cannabis growing operation in North America. Together, FV Pharma and Cannara have a combined floor space of over 1.245 million square feet of indoor growing capacity. read more

FSD Pharma Inc. Added to the CSE 25 Composite Index

FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) has been added to the CSE 25 Composite Index, effective after the close on Friday, June 15, 2018. The Company met index entry requirements and bypassed the typical seasoning period for a new entrant due to its placement in the top quartile of the Index. The Company is pleased to see FSD recognized so quickly as a “cream of the crop” new entrant on the Index. read more